var data={"title":"Piperacillin and tazobactam sodium: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Piperacillin and tazobactam sodium: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6784?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=piperacillin-and-tazobactam-sodium-patient-drug-information\" class=\"drug drug_patient\">see &quot;Piperacillin and tazobactam sodium: Patient drug information&quot;</a> and <a href=\"topic.htm?path=piperacillin-and-tazobactam-sodium-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Piperacillin and tazobactam sodium: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F210401\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Zosyn</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F210402\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>AJ-PIP/TAZ;</li>\n      <li>Piperacillin and Tazobactam for Injection;</li>\n      <li>Tazocin</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F210424\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antibiotic, Penicillin</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F210405\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Adult doses are expressed as the combined amount of piperacillin and tazobactam. Method of infusion: Dosing is presented based on traditional infusion method over 30 minutes, unless otherwise specified as the extended infusion method over 4 hours (off-label method).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Usual dosage range: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Traditional infusion method (over 30 minutes):</i> IV: Mild to moderate infections: 3.375 g every 6 hours; severe infections: 4.5 g every 6 to 8 hours (Cornely 2004; Gyssens 2011; Saltoglu 2010). For coverage of <i>Pseudomonas aeruginosa</i>: 4.5 g every 6 hours. Usual maximum dose: 18 g/day.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Extended infusion method (off-label method):</i> IV: 3.375 or 4.5 g every 8 hours infused over 4 hours (Lodise 2007; Shea 2009; Yang 2015).<b> Note</b>: Extended infusion method is supported by data suggesting equal or better attainment of pharmacokinetic targets and clinical benefit in patients with elevated risk of drug-resistant pathogens, severe infections, altered pharmacokinetics, and in other high-risk clinical situations (Lodise 2007; MacVane 2014; Moehring 2017a; Vardakas 2018).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <span style=\"text-decoration: underline\">\n        <b>Indication-specific dosing</b></span>\n      <b>:</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Bite wound infections (off-label use):</b>\n      <b> Note:</b> Additional coverage for methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) may be needed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Animal bite wound, prophylaxis for high-risk wound or treatment:</i> IV: 3.375 g every 6 to 8 hours. Duration for prophylaxis is 3 to 5 days (IDSA [Stevens 2014]); duration of treatment for established infection ranges from 5 to 14 days and varies based on clinical response and patient-specific factors (Baddour 2017a).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Human bite wound, prophylaxis or treatment:</i> IV: 4.5 g every 8 hours. Duration for prophylaxis is 3 to 5 days; duration of treatment for established infection ranges from 5 to 14 days based on clinical response and patient-specific factors. Complicated infections (eg, osteomyelitis) require prolonged therapy (Baddour 2017b).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Bloodstream infection</b> <b>(gram-negative bacteremia) (off-label use):</b> <b>Note:</b> For empiric therapy of known or suspected pseudomonal bloodstream infection in patients with neutropenia, severe burns, sepsis, or septic shock, give as part of an appropriate combination regimen (Kanj 2017a; Moehring 2017b; SCCM [Rhodes 2017]). Use of extended infusion method is preferred if severe infection, critically ill, or to optimize exposure if susceptible organism with elevated MIC. If critically ill with severe infection (including patients with neutropenic fever), first dose may be given over 30 minutes as a loading dose, followed 4 hours later by extended infusion (Moehring 2017a).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Community-acquired infection</i>, <i>immunocompetent host:</i> IV: 3.375 g every 6 hours (Moehring 2017b).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Health care-associated infection,</i> <i>including catheter-related, immunosuppressed host, or for coverage of</i> <i>Pseudomonas aeruginosa</i>: IV: 4.5 g every 6 hours (IDSA [Mermel 2009]; Moehring 2017b).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Duration of therapy:</i> Individualize duration according to patient-specific factors and response; usual duration is 7 to 14 days. If neutropenic, extend treatment until afebrile for 2 days and recovery of neutrophils (ANC &ge;500 cells/mm<sup>3</sup> and increasing) (IDSA [Freifeld 2011]). For <i>Pseudomonas</i> bacteremia in neutropenic patients, some experts treat for a minimum of 14 days and until recovery of neutrophils (Kanj 2017a).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cystic fibrosis, severe acute pulmonary exacerbation or failure of oral therapy, for coverage of <i>P. aeruginosa</i></b> <b>(off-label use):</b> IV: 4.5 g every 6 hours. <b>Note:</b> Most often given as part of an appropriate combination regimen, which should include an additional antipseudomonal agent (Flume 2012; Simon 2017). Use of extended infusion method may be considered (Zobell 2013; Simon 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Diabetic foot infection, moderate to severe: </b>IV: 3.375 g every 6 hours <b>or</b> 4.5 g every 8 hours (Gyssens 2011; Saltoglu 2010; Tan 1993). For treatment of <i>P. aeruginosa </i>infection: 4.5 g every 6 hours (Weintrob 2017). <b>Note: </b>Empiric <i>Pseudomonas </i>coverage with this dose is usually not indicated unless patient is at risk (eg, significant water exposure, warm climate) (IDSA [Lipsky 2012]; Weintrob 2017). In critically ill patients, use of extended infusion method is preferred (Moehring 2017a).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Duration of therapy:</i> Varies by patient specific factors; usual duration is 2 to 4 weeks (in the absence of osteomyelitis). May switch to oral agents when appropriate to complete course of therapy (IDSA [Lipsky 2012]; Weintrob 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Intra-abdominal infection</b>\n      <b>:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Appendicitis, perforated</i>: IV: 3.375 or 4.5 g every 6 hours for 4 to 7 days (IDSA [Solomkin 2010]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Diverticulitis, hospitalized patient</i>: IV: 3.375 or 4.5 g every 6 hours for 4 to 7 days (IDSA [Solomkin 2010]). Once stable, some experts transition to oral antibiotics to complete a 10 to 14 day total course of therapy (Pemberton 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Intra-abdominal abscess</i>\n      <b>:</b> IV: 3.375 or 4.5 g every 6 hours for 4 to 7 days following adequate source control (IDSA [Solomkin 2010]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Malignant (necrotizing) external otitis, hospitalized patients</b> <b>(alternative agent) (off-label use)</b>: IV: 4.5 g every 6 hours. Total duration of therapy, including oral step-down, is 6 to 8 weeks (Grandis 2018). In critically ill patients, use of extended infusion method is preferred (Moehring 2017a).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Neutropenic fever, high-risk cancer patients</b> <b>(ANC expected to be &le;100 cells/</b><b>mm<sup>3 </sup>for &gt;7 days, clinically unstable, or significant comorbidity) (off-label use)</b>: IV: 4.5 g every 6 to 8 hours until afebrile for &ge;48 hours and resolution of neutropenia (ANC &ge;500 cells/mm<sup>3 </sup>and increasing) or standard duration for the specific infection identified, if longer than the duration of neutropenia. If there is significant concern for <i>Pseudomonas</i> infection (particularly in those who are severely ill or were not receiving fluoroquinolone prophylaxis), 4.5 g every 6 hours should be given. Additional agent(s) may be needed depending on clinical status (IDSA [Freifeld 2011]; Wingard 2018). <b>Note:</b> Some experts consider patients expected to have an ANC &lt;500 cells/mm<sup>3 </sup>for &gt;7 days to be at high risk (Wingard 2018).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Use of extended infusion method is preferred in those who are critically ill; may give first dose over 30 minutes as a loading dose, followed 4 hours later by extended infusion (Moehring 2017a; SCCM [Rhodes 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pleural empyema </b>\n      <b>(hospital-acquired infection, immunocompromised host, or coverage of <i>P. aeruginosa</i>) (off-label use):</b> IV: 4.5 g every 6 hours (IDSA/ATS [Kalil 2016]). <b>Note:</b> Use in conjunction with surgical drainage. Additional agent for coverage of methicillin-resistant <i>S. aureus</i> may be needed in patents with hospital-acquired or postprocedural empyema (Psallidas 2014; Strange 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pneumonia:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Community-acquired pneumonia (CAP), as a component of empiric therapy for coverage of P. aeruginosa (hospitalized patient):</i> IV: 4.5 g every 6 hours in combination with other appropriate agent(s) for 5 to 7 days and individualized based on response to therapy (File 2017; IDSA/ATS [Mandell 2007]). A longer course (7 to 21 days) may be required if <i>P. aeruginosa</i> is the cause (Kanj 2017b). If critically ill, use of extended infusion method is preferred (Moehring 2017a).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Hospital-acquired or ventilator-associated pneumonia (HAP, VAP): </i>IV: 4.5 g every 6 hours, in combination with other agent(s) when appropriate, for 7 days and individualized based on response to therapy (IDSA/ATS [Kalil 2016]). A longer course may be required if <i>P. aeruginosa</i> is the cause (Kanj 2017b). If critically ill, use of extended infusion method is preferred (Moehring 2017a).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Sepsis and septic shock</b> <b>(broad-spectrum coverage, including <i>P.</i><i>aeruginosa) </i>(off-label use):</b> IV: 4.5 g every 6 hours in combination with other appropriate agent(s) (Kanj 2017d). Initiate therapy as soon as possible and within one hour of recognition of sepsis or septic shock. Usual duration of treatment is 7 to 10 days or longer depending upon clinical response (SCCM [Rhodes 2017]). Some experts prefer use of extended infusion method. May give first dose over 30 minutes as a loading dose, followed 4 hours later by extended infusion (Moehring 2017a; SCCM [Rhodes 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Skin and soft tissue infection, due to <i>P. aeruginosa</i>: </b>IV: 4.5 g every 6 hours. Usual duration of treatment is 10 to 14 days and is individualized based on response to therapy (Kanj 2017c). For severe infections, use of extended infusion method is preferred (Moehring 2017a).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Skin and soft tissue infection, necrotizing (broad-spectrum coverage of gram-positive [not including MRSA], gram-negative, and anaerobic pathogens) (off-label use):</b> IV: 3.375 g every 6 to 8 hours as part of an appropriate combination regimen. Continue until further debridement is not necessary, patient has improved clinically, and is afebrile for 48 to 72 hours (IDSA [Stevens 2014]). For severe infections, use of extended infusion method is preferred (Moehring 2017a).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Suppurative parotitis (acute bacterial) and deep neck space infections, health care-associated, immunocompromised host, or for coverage of <i>P. aeruginosa</i></b> <b>(off-label use):</b> IV: 4.5 g every 6 hours. For empiric therapy, given in combination with an agent appropriate for coverage of MRSA (Chow 2017a; Chow 2017b).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Duration of therapy:</i> 10 to 14 days (including oral step-down) for uncomplicated suppurative parotitis (Chow 2017a); &ge;2 to 3 weeks IV therapy for deep neck space infections (Chow 2017b).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Surgical site infections, incisional (eg, intestinal, genitourinary tract), warranting expanded coverage of gram-negative and anaerobic pathogens (off-label use):</b> IV: 3.375 g every 6 hours <b>or</b> 4.5 g every 8 hours (IDSA [Stevens 2014]). For treatment of <i>P. aeruginosa</i> infection: 4.5 g every 6 hours (Kanj 2017c). Duration is dependent upon severity, need for debridement, and clinical response (IDSA [Stevens 2014]). For severe infections, use of extended infusion method is preferred (Moehring 2017a).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F210418\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=piperacillin-and-tazobactam-sodium-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Piperacillin and tazobactam sodium: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Piperacillin and tazobactam is a combination product; each 3.375 g vial contains 3 g piperacillin sodium and 0.375 g tazobactam sodium in an 8:1 ratio. Dosage recommendations in <b>pediatric</b> patients are based on the <b>piperacillin</b> component. Dosing presented is based on traditional infusion method (IV infusion over 30 minutes) unless otherwise specified as the extended infusion method (IV infusion over 4 hours [off-label method]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Usual dosage range:</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants 2 to 9 months: 80 mg piperacillin/kg/dose every 8 hours (Red Book [AAP] 2012):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants &gt;9 months, Children, and Adolescents: 100 mg piperacillin/kg/dose every 8 hours (maximum dose: 16 g piperacillin/day) (Red Book [AAP] 2012):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children and Adolescents: Extended-infusion method: Limited data available: 100 mg piperacillin/kg/dose infused over 4 hours 3 times daily. Dosing based on a prospective, observational study (n=332) in a single children's hospital comparing the extended interval method to traditional dosing (Nichols 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Indication-specific dosing:</b> Infants, Children, and Adolescents: <b>Note:</b> In pediatric patients, dosage recommendations are based on the <b>piperacillin</b> component. Dosing is presented in mg/kg/<b>dose</b> and mg/kg/<b>day</b>; use caution.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Appendicitis, peritonitis:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants 2 to 9 months: IV: 80 mg piperacillin/kg/dose every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants &gt;9 months, Children, and Adolescents &le;40 kg: IV: 100 mg piperacillin/kg/dose every 8 hours (maximum: 3,000 mg piperacillin/dose)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children and Adolescents &gt;40 kg: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Cystic fibrosis, pseudomonal lung infections (off-label use):</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Standard dosing: IV: 240 to 400 mg piperacillin/kg/<b>day </b> divided every 8 hours (Kliegman, 2011); others have used 350 to 400 mg/kg/<b>day</b> divided every 4 hours in early piperacillin trials (Zobell, 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">High-dose: Limited data available: IV: 450 mg piperacillin/kg/<b>day</b> divided every 4 to 6 hours or 600 mg piperacillin/kg/<b>day</b> divided every 4 hours has been described from early studies of piperacillin alone; usual maximum daily dose: 18 to 24 g piperacillin/<b>day</b>. <b>Note:</b> Piperacillin doses &gt;600 mg/kg/day or an extended duration of therapy (&gt;14 days) have been associated with dose-related adverse effects including serum sickness, immune-mediated hemolytic anemia and bone marrow suppression (Zobell 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Endocarditis, treatment (off-label use): </b>Children and Adolescents: IV: 240 mg piperacillin/kg/<b>day</b> divided every 8 hours in combination with an aminoglycoside for at least 6 weeks; maximum daily dose: 18 <b>g</b> piperacillin/<b>day</b> (AHA [Baltimore 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Intra-abdominal infection, complicated (off-label use):</b> IV: 200 to 300 mg piperacillin/kg/day divided every 6 to 8 hours (maximum dose: 12 g piperacillin/day) (Solomkin 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Skin and soft tissue necrotizing infections (off-label use):</b> IV: 60 to 75 mg piperacillin/kg every 6 hours (in combination with vancomycin for empiric therapy); continue until further debridement is not necessary, patient has clinically improved, and patient is afebrile for 48 to 72 hours. (IDSA [Stevens 2014])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Surgical (perioperative) prophylaxis (off-label use): Note:</b> Doses may be repeated in 2 hours if procedure is lengthy or if there is excessive blood loss (Bratzler 2013): IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants 2 to 9 months: 80 mg piperacillin/kg within 60 minutes prior to surgical incision (maximum: 3,000 mg piperacillin/dose)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants &gt;9 months, Children, and Adolescents &le;40 kg: 100 mg piperacillin/kg within 60 minutes prior to surgical incision (maximum: 3,000 mg piperacillin/dose).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents weighing &gt;40 kg: 3,000 mg piperacillin 30 to 60 minutes prior to procedure</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F210406\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F210407\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Traditional infusion method (ie, IV infusion over 30 minutes): Manufacturer&rsquo;s labeling:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &gt;40 mL/minute: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 20 to 40 mL/minute: Administer 2.25 g every 6 hours (3.375 g every 6 hours for hospital-acquired or ventilator-associated pneumonia)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &lt;20 mL/minute: Administer 2.25 g every 8 hours (2.25 g every 6 hours for hospital-acquired or ventilator-associated pneumonia)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note:</b> Some clinicians suggest adjusting the dose at CrCl &le;20 mL/minute (rather than CrCl &lt;40 mL/minute) in patients receiving either traditional or extended-infusion methods, particularly if treating serious gram-negative infections (empirically or definitively) (Patel 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended infusion method (off-label dosing): CrCl &le;20 mL/minute: 3.375 g IV over 4 hours every 12 hours (Patel 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">End-stage renal disease (ESRD):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Intermittent hemodialysis (IHD): 2.25 g every 12 hours (2.25 g every 8 hours for hospital-acquired or ventilator-associated pneumonia); Hemodialysis removes 30% to 40% of a piperacillin/tazobactam dose. <b>Note:</b> Dosing dependent on the assumption of 3 times/week, complete IHD sessions. Administer scheduled doses after hemodialysis on dialysis days; if next regularly scheduled dose is not due right after dialysis session, administer an additional dose of 0.75 g after the dialysis session.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Peritoneal dialysis (PD): 2.25 g every 12 hours (2.25 g every 8 hours for hospital-acquired or ventilator-associated pneumonia); peritoneal dialysis removes 6% of piperacillin and 21% of tazobactam.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Continuous renal replacement therapy (CRRT) (Heintz 2009; Trotman 2005): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of pharmacologic response, signs of adverse reactions due to drug accumulation, as well as drug concentrations in relation to target trough (if appropriate). The following are general recommendations only (based on dialysate flow/ultrafiltration rates of 1 to 2 L/hour and minimal residual renal function) and should not supersede clinical judgment (Trotman 2005):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CVVH: 2.25 to 3.375 g every 6 to 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CVVHD: 2.25 to 3.375 g every 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CVVHDF: 3.375 g every 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note:</b> Higher dose of 3.375 g should be considered when treating resistant pathogens (especially <i>Pseudomonas</i> spp); alternative recommendations suggest dosing of 4.5 g every 8 hours (Valtonen 2001); regardless of regimen, there is some concern of tazobactam (TAZ) accumulation, given its lower clearance relative to piperacillin (PIP). Some clinicians advocate dosing with PIP to alternate with PIP/TAZ, particularly in CVVH-dependent patients, to lessen this concern.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Infants, Children, and Adolescents: There are no dosage adjustments provided in the manufacturer's labeling; however, the following adjustments have been recommended (Aronoff, 2007): Dosing based on a usual dose of 200 to 300 mg piperacillin/kg/day in divided doses every 6 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">GFR &gt;50 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">GFR 30 to 50 mL/minute/1.73 m<sup>2</sup>: 35 to 50 mg piperacillin/kg/dose every 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">GFR &lt;30 mL/minute/1.73 m<sup>2</sup>: 35 to 50 mg piperacillin/kg/dose every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">End-stage renal disease (ESRD) on intermittent hemodialysis (IHD): Hemodialysis removes 30% to 40% of a piperacillin/tazobactam dose: 50 to 75 mg piperacillin/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Peritoneal dialysis (PD): Peritoneal dialysis removes 21% of tazobactam and 6% of piperacillin: 50 to 75 mg piperacillin/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Continuous renal replacement therapy (CRRT): 35 to 50 mg piperacillin/kg/dose every 8 hours</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F210408\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment necessary.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F210378\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note</b>: 8:1 ratio of piperacillin sodium/tazobactam sodium</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Infusion [premixed iso-osmotic solution]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zosyn: 2.25 g: Piperacillin 2 g and tazobactam 0.25 g (50 mL) [contains edetate disodium, sodium 128 mg (5.58 mEq)] </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zosyn: 3.375 g: Piperacillin 3 g and tazobactam 0.375 g (50 mL)  [contains edetate disodium, sodium 192 mg (8.38 mEq)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zosyn: 4.5 g: Piperacillin 4 g and tazobactam 0.5 g (100 mL) [contains edetate disodium, sodium 256 mg (11.17 mEq)] </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Injection, powder for reconstitution: 2.25 g: Piperacillin 2 g and tazobactam 0.25 g; 3.375 g: Piperacillin 3 g and tazobactam 0.375 g; 4.5 g: Piperacillin 4 g and tazobactam 0.5 g; 40.5 g: Piperacillin 36 g and tazobactam 4.5 g</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zosyn: 2.25 g: Piperacillin 2 g and tazobactam 0.25 g [contains edetate disodium, sodium 130 mg (5.68 mEq)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zosyn: 3.375 g: Piperacillin 3 g and tazobactam 0.375 g [contains edetate disodium, sodium 195 mg (8.52 mEq)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zosyn: 4.5 g: Piperacillin 4 g and tazobactam 0.5 g [contains edetate disodium, sodium 260 mg (11.36 mEq)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zosyn: 40.5 g: Piperacillin 36 g and tazobactam 4.5 g [contains edetate disodium, sodium 2304 mg (100.4 mEq); bulk pharmacy vial]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F210362\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes: Excludes infusion</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F210382\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV: Administer by IV infusion over 30 minutes. For extended infusion administration (off-label method), administer over 4 hours (Shea 2009).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Some penicillins (eg, carbenicillin, ticarcillin, and piperacillin) have been shown to inactivate aminoglycosides <i>in vitro</i>. This has been observed to a greater extent with tobramycin and gentamicin, while amikacin has shown greater stability against inactivation. Concurrent use of these agents may pose a risk of reduced antibacterial efficacy <i>in vivo</i>, particularly in the setting of profound renal impairment. However, definitive clinical evidence is lacking. If combination penicillin/aminoglycoside therapy is desired in a patient with renal dysfunction, separation of doses (if feasible), and routine monitoring of aminoglycoside levels, CBC, and clinical response should be considered. <b>Note:</b> Reformulated Zosyn containing EDTA has been shown to be compatible <i>in vitro</i> for Y-site infusion with amikacin and gentamicin diluted in NS or D<sub>5</sub>W (applies <b>only</b> to specific concentrations and varies by product; consult manufacturer&rsquo;s labeling). Reformulated Zosyn containing EDTA is <b>not</b> compatible with tobramycin.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F210381\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Intra-abdominal infections:</b> Treatment of appendicitis complicated by rupture or abscess and peritonitis caused by beta-lactamase-producing strains of <i>Escherichia coli</i>, <i>Bacteroides fragilis</i>, <i>Bacteroides ovatus</i>, <i>Bacteroides thetaiotaomicron</i>, or <i>Bacteroides vulgatus</i>.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pelvic infections:</b> Treatment of postpartum endometriosis or pelvic inflammatory disease caused by beta-lactamase-producing strains of <i>E. coli</i>.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pneumonia, community-acquired:</b> Treatment of moderate severity community-acquired pneumonia (CAP) caused by beta-lactamase-producing strains of <i>Haemophilus influenzae</i>. Infectious Diseases Society of America/American Thoracic Society (IDSA/ATS) guidelines only recommend piperacillin/tazobactam for CAP caused by <i>P. aeruginosa</i> or due to aspiration (IDSA/ATS [Mandell 2007]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pneumonia, hospital-acquired (nosocomial):</b> Treatment of moderate to severe hospital-acquired (nosocomial) pneumonia caused by beta-lactamase-producing strains of <i>Staphylococcus aureus</i> and by piperacillin/tazobactam-susceptible <i>Acinetobacter baumanii</i>, <i>H. influenzae</i>, <i>Klebsiella pneumoniae</i>, and <i>Pseudomonas aeruginosa</i>.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Skin and skin structure infections:</b> Treatment of skin and skin structure infections, including cellulitis, cutaneous abscesses, and ischemic/diabetic foot infections caused by beta-lactamase-producing strains of <i>S. aureus</i>.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25470612\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Bite wound infections; Bloodstream infection (gram-negative bacteremia); Cystic fibrosis, exacerbation; Endocarditis, treatment (pediatric); Malignant (necrotizing) external otitis; Neutropenic fever, high-risk cancer patients; Pleural empyema (hospital-acquired infection, immunocompromised host, or coverage of P. aeruginosa); Sepsis and septic shock; Skin and soft tissue infection, necrotizing; Suppurative parotitis (acute bacterial) and deep neck space infections; Surgical site infections</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F210432\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Zosyn may be confused with Zofran, Zyvox</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Tazact [India] may be confused with Tazac brand name for nizatidine [Australia]; Tiazac brand name for dilTIAZem [US, Canada]</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F210369\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Also see piperacillin monograph.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%: Gastrointestinal: Diarrhea (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Phlebitis (1%), flushing (&le;1%), hypotension (&le;1%), thrombophlebitis (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (8%), insomnia (7%), rigors (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin rash (4%), pruritus (3%), purpura (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hypoglycemia (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Constipation (8%), nausea (7%), dyspepsia (3%), vomiting (3%), abdominal pain (1%), pseudomembranous colitis (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypersensitivity: Anaphylaxis (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Candidiasis (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Injection site reaction (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Arthralgia (&le;1%), myalgia (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Epistaxis (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not defined:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Decreased serum albumin, decreased serum glucose, decreased serum total protein, electrolyte disturbance (increases and decreases in sodium, potassium, and calcium), hyperglycemia, hypokalemia, increased gamma-glutamyl transferase</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Decreased hematocrit, decreased hemoglobin, eosinophilia, leukopenia, neutropenia, positive direct Coombs test, prolonged bleeding time, prolonged partial thromboplastin time, prolonged prothrombin time, thrombocythemia, thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased serum alkaline phosphatase, increased serum ALT, increased serum AST, increased serum bilirubin</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Increased blood urea nitrogen, increased serum creatinine, renal failure (in critically ill patients)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Acute generalized exanthemous pustulosis, agranulocytosis, anaphylactoid reaction, <i>Clostridium difficile-</i>associated diarrhea, convulsions, DRESS syndrome, eosinophilic pneumonitis, erythema multiforme, exfoliative dermatitis, hemolytic anemia, hepatitis, hypersensitivity reaction, interstitial nephritis, jaundice, pancytopenia, shock, Stevens-Johnson syndrome, toxic epidermal necrolysis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F210385\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to penicillins, cephalosporins, beta-lactamase inhibitors, or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F210366\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anaphylactoid/hypersensitivity reactions: Serious and occasionally severe or fatal hypersensitivity (anaphylactic/anaphylactoid) reactions have been reported in patients on penicillin therapy, especially with a history of beta-lactam hypersensitivity or history of sensitivity to multiple allergens. Discontinue treatment and institute appropriate therapy if an allergic reaction occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dermatologic effects: Serious skin reactions, including toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS), acute exanthematous pustulosis, and drug reaction with eosinophilia and systemic symptoms (DRESS) have been reported. If a skin rash develops, monitor closely. Discontinue if lesions progress.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Electrolyte abnormalities: Sodium content (2.84 mEq per gram of piperacillin) should be considered in patients requiring sodium restriction. Assess electrolytes periodically in patients with low potassium reserves, especially those receiving cytotoxic therapy or diuretics.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hematologic effects: Prothrombin time, platelet aggregation, and clotting time abnormalities have been reported with piperacillin and particularly in patients with renal impairment. Discontinue if thrombocytopenia or bleeding occurs. Leukopenia/neutropenia may occur; appears to be reversible and most frequently associated with prolonged administration. Assess hematologic parameters periodically, especially with prolonged (&ge;21 days) use.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Superinfection: Use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cystic fibrosis: An increased frequency of fever and rash has been reported in patients with cystic fibrosis receiving piperacillin.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment or in hemodialysis patients. Dosage adjustment recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizure disorders: Use with caution in patients with a history of seizure disorder; high levels, particularly in the presence of renal impairment, may increase risk of seizures.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Critically ill patients: Use of piperacillin and tazobactam in critically ill patients may delay renal recovery as compared to other beta-lactam antibacterial drugs; consider alternative treatment options in critically ill patients. If alternative treatment options are inadequate or unavailable, closely monitor renal function.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Concurrent drug therapy issues:</b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299884\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F210371\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9777&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Acemetacin: May increase the serum concentration of Penicillins.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aminoglycosides: Penicillins may decrease the serum concentration of Aminoglycosides. Primarily associated with extended spectrum penicillins, and patients with renal dysfunction. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flucloxacillin: Piperacillin may increase the serum concentration of Flucloxacillin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrexate: Penicillins may increase the serum concentration of Methotrexate. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mycophenolate: Penicillins may decrease serum concentrations of the active metabolite(s) of Mycophenolate. This effect appears to be the result of impaired enterohepatic recirculation. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probenecid: May increase the serum concentration of Penicillins. Management: Avoid the routine use of penicillins and probenecid, but this combination may be used advantageously in select cases with careful monitoring. Monitor for toxic effects of penicillins if probenecid is initiated or the dose is increased.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetracyclines: May diminish the therapeutic effect of Penicillins.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vancomycin: Piperacillin may enhance the nephrotoxic effect of Vancomycin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vecuronium: Piperacillin may enhance the neuromuscular-blocking effect of Vecuronium. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Penicillins may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F210387\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Piperacillin and tazobactam both cross the placenta and are found in the fetal serum, placenta, amniotic fluid, and fetal urine. When used during pregnancy, the clearance and volume of distribution of piperacillin/tazobactam are increased; half-life and AUC are decreased (Bourget 1998). Piperacillin/tazobactam is approved for the treatment of postpartum gynecologic infections, including endometritis or pelvic inflammatory disease, caused by susceptible organisms.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F210388\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Low concentrations of piperacillin are present in breast milk; information for tazobactam is not available. According to the manufacturer, the decision to continue or discontinue breastfeeding during therapy should take into account the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother. In general, antibiotics that are present in breast milk may cause nondose-related modification of bowel flora. Monitor infants for GI disturbances (WHO 2002).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F210389\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Some products may contain sodium.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F210376\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Creatinine, BUN, CBC with differential, PT, PTT, serum electrolytes, LFTs, urinalysis; signs of bleeding; monitor for signs of anaphylaxis during first dose</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F210365\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Piperacillin inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs); which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested. Piperacillin exhibits time-dependent killing. Tazobactam inhibits many beta-lactamases, including staphylococcal penicillinase and Richmond-Sykes types 2, 3, 4, and 5, including extended spectrum enzymes; it has only limited activity against class 1 beta-lactamases other than class 1C types.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F210384\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Note: </b>Both AUC and peak concentrations are dose proportional </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Well into lungs, intestinal mucosa, uterus, ovary, fallopian tube, interstitial fluid, gallbladder, and bile; penetration into CSF is low in subjects with noninflamed meninges; V<sub>d</sub>: Children and Adults: 0.243 L/kg </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: Piperacillin: ~26% to 33%; Tazobactam: 31% to 32% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Piperacillin: 6% to 9% to desethyl metabolite (weak activity) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Tazobactam: ~22% to inactive metabolite </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: IM: Piperacillin: 71%; Tazobactam: 84%  </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination (pediatric data: Reed 1994): </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Piperacillin: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Infants 2 to 5 months: 1.4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Infants and Children 6 to 23 months: 0.9 hour</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Children 2 to 12 years: 0.7 hour</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Adults: 0.7 to 1.2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Metabolite: 1 to 1.5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Tazobactam: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Infants 2 to 5 months: 1.6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Infants and Children 6 to 23 months: 1 hour</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Children 2 to 12 years: 0.8 to 0.9 hour </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Adults: 0.7 to 0.9 hour </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, plasma: Immediately following completion of 30-minute infusion</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Clearance of both piperacillin and tazobactam are directly proportional to renal function; Infants and Children 9 months to 12 years: 5.64 mL/minute/kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Piperacillin: Urine (68% as unchanged drug); feces (10% to 20%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Tazobactam: Urine (80% as unchanged drug; remainder as inactive metabolite)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6856652\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Zosyn Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2-0.25 gm/50 mL (50 mL): $18.31</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3-0.375 gm/50 mL (50 mL): $27.47</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4-0.5 g/100 mL (100 mL): $34.81</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Piperacillin Sod-Tazobactam So Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.25 (2-0.25) g (1): $8.40</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3.375 (3-0.375) g (1): $13.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4.5 (4-0.5) g (1): $17.40</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">13.5 (12-1.5) g (1): $58.32</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40.5 (36-4.5) g (1): $176.10</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Zosyn Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.25 (2-0.25) g (1): $8.24</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3.375 (3-0.375) g (1): $12.36</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4.5 (4-0.5) g (1): $16.48</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40.5 (36-4.5) g (1): $151.20</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F210390\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Albactam (TH);</li>\n      <li>Ampito (LK);</li>\n      <li>Astaz-P (TH);</li>\n      <li>Aurotaz (QA);</li>\n      <li>Betamycin (TW);</li>\n      <li>Co-Tazo (TW);</li>\n      <li>Jeita (TW);</li>\n      <li>Pipercin (IE);</li>\n      <li>Pipertaz (TH);</li>\n      <li>Piptabac (CR, DO, EC, GT, HN, NI, PA, SV);</li>\n      <li>Piptaz (PH, VN);</li>\n      <li>Pisa (LK);</li>\n      <li>Plepra-T 4.5 (PH);</li>\n      <li>Pletzolyn (PH);</li>\n      <li>Prizma (QA);</li>\n      <li>Pybactam (ID);</li>\n      <li>Sixacin (PY);</li>\n      <li>Tabaxin (KR);</li>\n      <li>Tapicin (MY);</li>\n      <li>Tasovak (MX);</li>\n      <li>Tazar (UA);</li>\n      <li>Tazepen (MT);</li>\n      <li>Tazin (LK);</li>\n      <li>Tazobac (CH, DE, LI);</li>\n      <li>Tazobact (HR);</li>\n      <li>Tazobak (LK, PH);</li>\n      <li>Tazocillin (BD, IL);</li>\n      <li>Tazocilline (FR);</li>\n      <li>Tazocin (AE, BE, BG, BH, BR, CN, CO, CR, CY, CZ, DK, EC, EE, EG, GB, GT, HK, HN, HR, ID, IE, IL, IQ, IR, IT, JO, KR, KW, LB, LI, LT, LU, LY, MT, MX, NI, NL, OM, PA, PE, PH, PK, PL, QA, RO, SA, SE, SG, SI, SK, SV, SY, TH, TR, TW, VN, YE);</li>\n      <li>Tazocin EF (AU, DO, MY, NZ);</li>\n      <li>Tazomax (UY);</li>\n      <li>Tazonam (AR, AT, CL, PY);</li>\n      <li>Tazopen (BD, PH);</li>\n      <li>Tazoperan (KR);</li>\n      <li>Tazopip (AU, IL);</li>\n      <li>Tazopril (VE);</li>\n      <li>Tazorex (IL, MT);</li>\n      <li>Tazosyn (BD);</li>\n      <li>Tazpen (MY, SG, UA);</li>\n      <li>Tebranic (TH);</li>\n      <li>Victalis (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Vigocid (PH);</li>\n      <li>Zobaction (LK);</li>\n      <li>Zopercin (VN);</li>\n      <li>Zopertsyn (UA);</li>\n      <li>Zosyn (BB, IN, JP, LI)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>. 5th ed. Philadelphia, PA: American College of Physicians; 2007, p 61, 153.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      Baddour LM. Soft tissue infections due to dog and cat bites. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed August 10, 2017a.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      Baddour LM. Soft tissue infections due to human bites. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed August 10, 2017b.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baltimore RS, Gewitz M, Baddour LM, et al; American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young and the Council on Cardiovascular and Stroke Nursing. Infective endocarditis in childhood: 2015 update: a scientific statement from the American Heart Association. <i>Circulation.</i> 2015;132(15):1487-1515. doi: 10.1161/CIR.0000000000000298.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/piperacillin-and-tazobactam-sodium-drug-information/abstract-text/26373317/pubmed\" target=\"_blank\" id=\"26373317\">26373317</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bourget P, Sertin A, Lesne-Hulin A, et al. Influence of Pregnancy on the Pharmacokinetic Behaviour and the Transplacental Transfer of the Piperacillin-Tazobactam Combination. <i>Eur J Obstet Gynecol Reprod Biol.</i> 1998;76(1):21-27.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/piperacillin-and-tazobactam-sodium-drug-information/abstract-text/9481541/pubmed\" target=\"_blank\" id=\"9481541\">9481541</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"16838234\"></a>Bow EJ, Rotstein C, Noskin GA, et al. A randomized, open-label, multicenter comparative study of the efficacy and safety of piperacillin-tazobactam and cefepime for the empirical treatment of febrile neutropenic episodes in patients with hematologic malignancies. <i>Clin Infect Dis</i>. 2006;43(4):447-459. doi: 10.1086/505393.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/piperacillin-and-tazobactam-sodium-drug-information/abstract-text/16838234/pubmed\" target=\"_blank\" id=\"16838234\">16838234</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bratzler DW, Dellinger EP, Olsen KM, et al. Clinical Practice Guidelines for Antimicrobial Prophylaxis in Surgery. <i>Am J Health Syst Pharm.</i> 2013;70(3):195-283.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/piperacillin-and-tazobactam-sodium-drug-information/abstract-text/23327981/pubmed\" target=\"_blank\" id=\"23327981\">23327981</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bryson HM and Brogden RN. Piperacillin/Tazobactam. A Review of its Antibacterial Activity, Pharmacokinetic Properties, and Therapeutic Potential. <i>Drugs.</i> 1994;47(3):506-535.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/piperacillin-and-tazobactam-sodium-drug-information/abstract-text/7514977/pubmed\" target=\"_blank\" id=\"7514977\">7514977</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chow MS, Quintiliani, Nightingale CH. <i>In Vivo</i> Inactivation of Tobramycin by Ticarcillin. A Case Report. <i>JAMA.</i> 1982;247(5):658-659.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/piperacillin-and-tazobactam-sodium-drug-information/abstract-text/6798229/pubmed\" target=\"_blank\" id=\"6798229\">6798229</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      Chow AW. Suppurative parotitis in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed December 28, 2017a.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      Chow AW. Deep neck space infections. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed December 28, 2017b.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"14979482\"></a>Cornely OA, Wicke T, Seifert H, et al. Once-daily oral levofloxacin monotherapy versus piperacillin/tazobactam three times a day: a randomized controlled multicenter trial in patients with febrile neutropenia. <i>Int J Hematol</i>. 2004;79(1):74-78.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/piperacillin-and-tazobactam-sodium-drug-information/abstract-text/14979482/pubmed\" target=\"_blank\" id=\"14979482\">14979482</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Daly JS, Dodge RA, Glew RH, et al. Effect of Time and Temperature on Inactivation of Aminoglycosides by Ampicillin at Neonatal Dosages. <i>J Perinatol.</i> 1997;17(1):42-55.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/piperacillin-and-tazobactam-sodium-drug-information/abstract-text/9069064/pubmed\" target=\"_blank\" id=\"9069064\">9069064</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DHHS Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. October 2014. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a>. Accessed November 12, 2014</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dowell JA, Korth-Bradley J, Milisci M, et al. Evaluating Possible Pharmacokinetic Interactions Between Tobramycin, Piperacillin, and a Combination of Piperacillin and Tazobactam in Patients With Various Degrees of Renal Impairment. <i>J Clin Pharmacol.</i> 2001;41:979-986.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/piperacillin-and-tazobactam-sodium-drug-information/abstract-text/11549103/pubmed\" target=\"_blank\" id=\"11549103\">11549103</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Farchione LA. Inactivation of Aminoglycosides by Penicillins. <i>J Antimicrob Chemother.</i> 1982;8(suppl A):27-36.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      File TM. Treatment of community-acquired pneumonia in adults who require hospitalization. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed December 28, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23319691\"></a>Flowers CR, Seidenfeld J, Bow EJ, et al. Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline. <i>J Clin Oncol</i>. 2013;31(6):794-810. doi: 10.1200/JCO.2012.45.8661.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/piperacillin-and-tazobactam-sodium-drug-information/abstract-text/23319691/pubmed\" target=\"_blank\" id=\"23319691\">23319691</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19729669\"></a>Flume PA, Mogayzel PJ Jr, Robinson KA, et al; Clinical Practice Guidelines for Pulmonary Therapies Committee. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. <i>Am J Respir Crit Care Med</i>. 2009;180(9):802-808. doi: 10.1164/rccm.200812-1845PP.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/piperacillin-and-tazobactam-sodium-drug-information/abstract-text/19729669/pubmed\" target=\"_blank\" id=\"19729669\">19729669</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21258094\"></a>Freifeld AG, Bow EJ, Sepkowitz KA, et al; Infectious Diseases Society of America. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. <i>Clin Infect Dis</i>. 2011;52(4):e56-e93. doi: 10.1093/cid/cir073.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/piperacillin-and-tazobactam-sodium-drug-information/abstract-text/21258094/pubmed\" target=\"_blank\" id=\"21258094\">21258094</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fuchs PC, Stickel S, Anderson PH, et al. <i>In Vitro</i> Inactivation of Aminoglycosides by Sulbactam, Other Beta-Lactams, and Sulbactam-Beta-Lactam Combinations. <i>Antimicrob Agents Chemother.</i> 1991;35(1):182-184.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/piperacillin-and-tazobactam-sodium-drug-information/abstract-text/2014975/pubmed\" target=\"_blank\" id=\"2014975\">2014975</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      Grandis JR. Malignant (necrotizing) external otitis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed February 28, 2018.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21896561\"></a>Gyssens IC, Dryden M, Kujath P, et al. A randomized trial of the efficacy and safety of sequential intravenous/oral moxifloxacin monotherapy versus intravenous piperacillin/tazobactam followed by oral amoxicillin/clavulanate for complicated skin and skin structure infections. <i>J Antimicrob Chemother</i>. 2011;66(11):2632-42. doi: 10.1093/jac/dkr344.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/piperacillin-and-tazobactam-sodium-drug-information/abstract-text/21896561/pubmed\" target=\"_blank\" id=\"21896561\">21896561</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Halstenson CE, Wong MO, Herman CS, et al. Effect of Concomitant Administration of Piperacillin on the Dispositions on Isepamicin and Gentamicin in Patients With End-Stage Renal Disease. <i>Antimicrob Agents Chemother.</i> 1992;36(9):1832-1836.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/piperacillin-and-tazobactam-sodium-drug-information/abstract-text/1416875/pubmed\" target=\"_blank\" id=\"1416875\">1416875</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Heintz BH, Matzke GR, Dager WE. Antimicrobial Dosing Concepts and Recommendations for Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy or Intermittent Hemodialysis. <i>Pharmacotherapy. </i>2009;29(5):562-577.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/piperacillin-and-tazobactam-sodium-drug-information/abstract-text/19397464/pubmed\" target=\"_blank\" id=\"19397464\">19397464</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hitt CM, Patel KB, Nicolau DP, et al. Influence of Piperacillin-Tazobactam on Pharmacokinetics of Gentamicin Given Once Daily. <i>Am J Health Syst Pharm.</i> 1997;54(23):2704-2708.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/piperacillin-and-tazobactam-sodium-drug-information/abstract-text/9408514/pubmed\" target=\"_blank\" id=\"9408514\">9408514</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society [published online July 14, 2016]. <i>Clin Infect Dis</i>. doi: 10.1093/cid/ciw353.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/piperacillin-and-tazobactam-sodium-drug-information/abstract-text/27418577/pubmed\" target=\"_blank\" id=\"27418577\">27418577</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      Kanj SS. Pseudomonas aeruginosa bacteremia and endocarditis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed August 10, 2017a.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      Kanj SS. Pseudomonas aeruginosa pneumonia. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed August 10, 2017b.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      Kanj SS. Principles of antimicrobial therapy of Pseudomonas aeruginosa infections. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed December 28, 2017c.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kim A, Sutherland CA, Kuti JL, et al. Optimal Dosing of Piperacillin-Tazobactam for the Treatment of <i>Pseudomonas aeruginosa</i> Infections: Prolonged or Continuous infusion. <i>Pharmacother.</i> 2007;27(11):1490-1497.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/piperacillin-and-tazobactam-sodium-drug-information/abstract-text/17963458/pubmed\" target=\"_blank\" id=\"17963458\">17963458</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kim M-K, Capitano B, Mattoes HM, et al. Pharmacokinetic and Pharmacodynamic Evaluation of Two Dosing Regimens for Piperacillin-Tazobactam. <i>Pharmacother. </i>2002;22(5):569-577.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Konishi H, Goto M, Nakamoto Y, et al. Tobramycin Inactivation by Carbenicillin, Ticarcillin, and Piperacillin. <i>Antimicrob Agents Chemother.</i> 1983;23(5):653-657.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/piperacillin-and-tazobactam-sodium-drug-information/abstract-text/6223576/pubmed\" target=\"_blank\" id=\"6223576\">6223576</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lambourne J, Kitchen J, Hughes C, et al. Piperacillin/Tazobactam-Induced Paresthesiae. <i>Ann Pharmacother.</i> 2006;40(5):977-979.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/piperacillin-and-tazobactam-sodium-drug-information/abstract-text/16622157/pubmed\" target=\"_blank\" id=\"16622157\">16622157</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lau A, Lee M, Flascha S, et al. Effect of Piperacillin on Tobramycin Pharmacokinetics in Patients with Normal Renal Function. <i>Antimicrob Agents Chemother.</i> 1983;24(4):533-537.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/piperacillin-and-tazobactam-sodium-drug-information/abstract-text/6651279/pubmed\" target=\"_blank\" id=\"6651279\">6651279</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lipsky BA, Berendt AR, Cornia PB, et al. 2012 Infectious Diseases Society of America Clinical Practice Guideline for the Diagnosis and Treatment of Diabetic Foot Infections. <i>Clin Infect Dis.</i> 2012;54(12):e132-e173.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/piperacillin-and-tazobactam-sodium-drug-information/abstract-text/22619242/pubmed\" target=\"_blank\" id=\"22619242\">22619242</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17205441\"></a>Lodise TP Jr, Lomaestro B, Drusano GL. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. <i>Clin Infect Dis</i>. 2007;44(3):357-363. doi: 10.1086/510590.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/piperacillin-and-tazobactam-sodium-drug-information/abstract-text/17205441/pubmed\" target=\"_blank\" id=\"17205441\">17205441</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"24359838\"></a>MacVane SH, Kuti JL, Nicolau DP. Prolonging &beta;-lactam infusion: a review of the rationale and evidence, and guidance for implementation. <i>Int J Antimicrob Agents</i>. 2014;43(2):105-13. doi: 10.1016/j.ijantimicag.2013.10.021.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/piperacillin-and-tazobactam-sodium-drug-information/abstract-text/24359838/pubmed\" target=\"_blank\" id=\"24359838\">24359838</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22274145\"></a>Mah GT, Mabasa VH, Chow I, Ensom MH. Evaluating outcomes associated with alternative dosing strategies for piperacillin/tazobactam: a qualitative systematic review. <i>Ann Pharmacother</i>. 2012;46(2):265-275. doi: 10.1345/aph.1Q378.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/piperacillin-and-tazobactam-sodium-drug-information/abstract-text/22274145/pubmed\" target=\"_blank\" id=\"22274145\">22274145</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults. <i>Clin Infect Dis.</i> 2007;44(suppl 2):27-72.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/piperacillin-and-tazobactam-sodium-drug-information/abstract-text/17278083/pubmed\" target=\"_blank\" id=\"17278083\">17278083</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19489710\"></a>Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America [published correction appears in: <i>Clin Infect Dis</i>. 2010;50(7):1079; dosage error in article text: <i>Clin Infect Dis</i>. 2010;50(3):457.]. <i>Clin Infect Dis</i>. 2009;49(1):1-45. doi: 10.1086/599376.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/piperacillin-and-tazobactam-sodium-drug-information/abstract-text/19489710/pubmed\" target=\"_blank\" id=\"19489710\">19489710</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      Moehring R. Prolonged infusions of beta-lactam antibiotics. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed December 28, 2017a.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      Moehring R. Gram-negative bacillary bacteremia in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed August 10, 2017b.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <i>Nelson Textbook of Pediatrics</i>, 17th ed, Behrman RE, Kliegman RM, and Jenson HB, eds, Philadelphia, PA: WB Saunders Co, 2004.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Patel N, Scheetz MH, Drusano GL, et al. Identification of Optimal Renal Dosage Adjustments for Traditional and Extended-Infusion Piperacillin-Tazobactam Dosing Regimens in Hospitalized Patients. <i>Antimicrob Agents Chemother.</i> 2010;54(1):460-465.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/piperacillin-and-tazobactam-sodium-drug-information/abstract-text/19858253/pubmed\" target=\"_blank\" id=\"19858253\">19858253</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Perez-Vazquez A, Pastor JM, Riancho JA. Immune Thrombocytopenia Caused by Piperacillin/Tazobactam. <i>Clin Infect Dis.</i> 1998;27(3):650-651.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/piperacillin-and-tazobactam-sodium-drug-information/abstract-text/9770174/pubmed\" target=\"_blank\" id=\"9770174\">9770174</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      Pemberton JH. Acute colonic diverticulitis: Medical management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed December 28, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"25463162\"></a>Psallidas I, Corcoran JP, Rahman NM. Management of parapneumonic effusions and empyema. <i>Semin Respir Crit Care Med</i>. 2014;35(6):715-722. doi: 10.1055/s-0034-1395503.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/piperacillin-and-tazobactam-sodium-drug-information/abstract-text/25463162/pubmed\" target=\"_blank\" id=\"25463162\">25463162</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reed MD, Goldfarb J, Yamashita T, et al. Single-Dose Pharmacokinetics of Piperacillin and Tazobactam in Infants and Children. <i>Antimicrob Agents Chemother.</i> 1994;38(12):2817-2826.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/piperacillin-and-tazobactam-sodium-drug-information/abstract-text/7695268/pubmed\" target=\"_blank\" id=\"7695268\">7695268</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reed MD. The Pathophysiology and Treatment of Cystic Fibrosis. <i>J Pediatr Pharm Pract.</i> 1997;2:285&ndash;305.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reichardt P, Handrick W, Linke A, et al. Leukocytopenia, Thrombocytopenia and Fever Related to Piperacillin/Tazobactam Treatment &minus; a Retrospective Analysis in 38 Children With Cystic Fibrosis. <i>Infection.</i> 1999;27(6):355-356.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/piperacillin-and-tazobactam-sodium-drug-information/abstract-text/10624596/pubmed\" target=\"_blank\" id=\"10624596\">10624596</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"28098591\"></a>Rhodes A, Evans LE, Alhazzani W, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. <i>Crit Care Med</i>. 2017;45(3):486-552. doi: 10.1097/CCM.0000000000002255.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/piperacillin-and-tazobactam-sodium-drug-information/abstract-text/28098591/pubmed\" target=\"_blank\" id=\"28098591\">28098591</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"24867788\"></a>Rhodes NJ, MacVane SH, Kuti JL, Scheetz MH. Impact of loading doses on the time to adequate predicted beta-lactam concentrations in prolonged and continuous infusion dosing schemes. <i>Clin Infect Dis</i>. 2014;59(6):905-907. doi:10.1093/cid/ciu402.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/piperacillin-and-tazobactam-sodium-drug-information/abstract-text/24867788/pubmed\" target=\"_blank\" id=\"24867788\">24867788</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Russoe ME and Atkins-Thor E. Gentamicin and Ticarcillin in Subjects With End-Stage Renal Disease. Comparison of Two Assay Methods and Evaluation of Inactivation Rate. <i>Clin Nephrol.</i> 1981;15(4):175-180.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/piperacillin-and-tazobactam-sodium-drug-information/abstract-text/7237864/pubmed\" target=\"_blank\" id=\"7237864\">7237864</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19832720\"></a>Saltoglu N, Dalkiran A, Tetiker T, et al. Piperacillin/tazobactam versus imipenem/cilastatin for severe diabetic foot infections: a prospective, randomized clinical trial in a university hospital. <i>Clin Microbiol Infect</i>. 2010;16(8):1252-1257. doi: 10.1111/j.1469-0691.2009.03067.x.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/piperacillin-and-tazobactam-sodium-drug-information/abstract-text/19832720/pubmed\" target=\"_blank\" id=\"19832720\">19832720</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sanders WE Jr, Sanders CC. Piperacillin/Tazobactam: A Critical Review of the Evolving Clinical Literature. <i>Clin Infect Dis.</i> 1996;22(1):107-123.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/piperacillin-and-tazobactam-sodium-drug-information/abstract-text/8824974/pubmed\" target=\"_blank\" id=\"8824974\">8824974</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schoonover LL, Occhipinti DJ, Rodvold KA, et al. Piperacillin/Tazobactam: A New Beta-Lactam/Beta-Lactamase Inhibitor Combination. <i>Ann Pharmacother.</i> 1995;29(5):501-514.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/piperacillin-and-tazobactam-sodium-drug-information/abstract-text/7655135/pubmed\" target=\"_blank\" id=\"7655135\">7655135</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shea KM, Cheatham SC, Smith DW, et al. Comparative Pharmacodynamics of Intermittent and Prolonged Infusions of Piperacillin/Tazobactam Using Monte Carlo Simulations and Steady-State Pharmacokinetic Data from Hospitalized Patients. <i>Ann Pharmacother.</i> 2009;43(11):1747-1754.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/piperacillin-and-tazobactam-sodium-drug-information/abstract-text/19809009/pubmed\" target=\"_blank\" id=\"19809009\">19809009</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      Simon RH. Cystic fibrosis: Treatment of acute pulmonary exacerbations. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed August 10, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and Management of Complicated Intra-Abdominal Infections in Adults and Children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. <i>Clin Infect Dis.</i> 2010;50(2):133-164.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/piperacillin-and-tazobactam-sodium-drug-information/abstract-text/20034345/pubmed\" target=\"_blank\" id=\"20034345\">20034345</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sorgel F, Kinzig M. The Chemistry, Pharmacokinetics and Tissue Distribution of Piperacillin/Tazobactam. <i>J Antimicrob Chemother. </i>1993;31(suppl A):39-60.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America [published online June 18, 2014]. <i>Clin Infect Dis</i>. 2014;59(2):e10-52. doi: 10.1093/cid/ciu296.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/piperacillin-and-tazobactam-sodium-drug-information/abstract-text/24947530/pubmed\" target=\"_blank\" id=\"24947530\">24947530</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"24973422\"></a>Stevens DL, Bisno AL, Chambers HF, et al; Infectious Diseases Society of America. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America [published correction appears in:<i> Clin Infect Dis</i>. 2015 May 1;60(9):1448.] . <i>Clin Infect Dis</i>. 2014;59(2):e10-e52. doi: 10.1093/cid/ciu444.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/piperacillin-and-tazobactam-sodium-drug-information/abstract-text/24973422/pubmed\" target=\"_blank\" id=\"24973422\">24973422</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      Strange C. Parapneumonic effusion and empyema in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed December 28, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"8215266\"></a>Tan JS, Wishnow RM, Talan DA, Duncanson FP, Norden CW. Treatment of hospitalized patients with complicated skin and skin structure infections: double-blind, randomized, multicenter study of piperacillin-tazobactam versus ticarcillin-clavulanate. The Piperacillin/Tazobactam Skin and Skin Structure Study Group.<i> Antimicrob Agents Chemother</i>. 1993;37(8):1580-1586.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/piperacillin-and-tazobactam-sodium-drug-information/abstract-text/8215266/pubmed\" target=\"_blank\" id=\"8215266\">8215266</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <i>Teddy Bear Book: Pediatric Injectable Drugs</i>, 7th ed, Phelps SJ and Hak EB, eds, Bethesda, MD: American Society of Health-System Pharmacists, 2003.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Thompson MIB, Russo ME, Saxon BJ, et al. Gentamicin Inactivation by Piperacillin or Carbenicillin in Patients With End-Stage Renal Disease. <i>Antimicrob Agents Chemother.</i> 1982;21(2):268-273.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/piperacillin-and-tazobactam-sodium-drug-information/abstract-text/6462107/pubmed\" target=\"_blank\" id=\"6462107\">6462107</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Trotman RL, Williamson JC, Shoemaker DM, et al. Antibiotic Dosing in Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy. <i>Clin Infect Dis. </i>2005;41(8):1159-1166.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/piperacillin-and-tazobactam-sodium-drug-information/abstract-text/16163635/pubmed\" target=\"_blank\" id=\"16163635\">16163635</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Valtonen M, Tiula E, Takkunen O, et al. Elimination of the Piperacillin/Tazobactam Combination During Continuous Venovenous Haemofiltration and Haemodiafiltration in Patients With Acute Renal Failure. <i>J Antimicrob Chemother.</i> 2001;48(6):881-885.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/piperacillin-and-tazobactam-sodium-drug-information/abstract-text/11733473/pubmed\" target=\"_blank\" id=\"11733473\">11733473</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    van der Werf TS, Mulder PO, Zijlstra JG, et al. Pharmacokinetics of Piperacillin and Tazobactam in Critically Ill Patients With Renal Failure, Treated With Continuous Veno-Venous Hemofiltration (CVVH). <i>Intensive Care Med.</i> 1997;23(8):873-877.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/piperacillin-and-tazobactam-sodium-drug-information/abstract-text/9310805/pubmed\" target=\"_blank\" id=\"9310805\">9310805</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"29102324\"></a>Vardakas KZ, Voulgaris GL, Maliaros A, Samonis G, Falagas ME. Prolonged versus short-term intravenous infusion of antipseudomonal &beta;-lactams for patients with sepsis: a systematic review and meta-analysis of randomised trials. <i>Lancet Infect Dis</i>. 2018;18(1):108-120. doi: 10.1016/S1473-3099(17)30615-1.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/piperacillin-and-tazobactam-sodium-drug-information/abstract-text/29102324/pubmed\" target=\"_blank\" id=\"29102324\">29102324</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Viollier AF, Standiford HC, Drusano GL, et al. Comparative Pharmacokinetics and Serum Bactericidal Activity of Mezlocillin, Ticarcillin and Piperacillin, With and Without Gentamicin. <i>J Antimicrob Chemother.</i> 1985;15(5):597-606.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/piperacillin-and-tazobactam-sodium-drug-information/abstract-text/4008387/pubmed\" target=\"_blank\" id=\"4008387\">4008387</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Walterspiel JN, Feldman S, Van R, et al. Comparative Inactivation of Isepamicin, Amikacin, and Gentamicin by Nine Beta-Lactams and Two Beta-Lactamase Inhibitors, Cilastatin and Heparin. <i>Antimicrob Agents Chemother.</i> 1991;35(9):1875-1878.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/piperacillin-and-tazobactam-sodium-drug-information/abstract-text/1952861/pubmed\" target=\"_blank\" id=\"1952861\">1952861</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      Weintrob AC. Clinical manifestations, diagnosis, and management of diabetic infections of the lower Extremities. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed December 28, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      Wingard JR. Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients). Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. 2018.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"8383659\"></a>Wise R. The efficacy and safety of piperacillin/tazobactam in the therapy of bacteraemia. <i>J Antimicrob Chemother</i>. 1993;31(suppl A):97-104.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/piperacillin-and-tazobactam-sodium-drug-information/abstract-text/8383659/pubmed\" target=\"_blank\" id=\"8383659\">8383659</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO). Breastfeeding and Maternal Medication, Recommendations for Drugs in the Eleventh WHO Model List of Essential Drugs. 2002.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21814800\"></a>Yamagishi Y, Terada M, Ohki E, Miura Y, Umemura T, Mikamo H. Investigation of the clinical breakpoints of piperacillin-tazobactam against infections caused by <i>Pseudomonas aeruginosa</i>. <i>J Infect Chemother</i>. 2012;18(1):127-129. doi: 10.1007/s10156-011-0285-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/piperacillin-and-tazobactam-sodium-drug-information/abstract-text/21814800/pubmed\" target=\"_blank\" id=\"21814800\">21814800</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"25575030\"></a>Yang H, Zhang C, Zhou Q, Wang Y, Chen L. Clinical outcomes with alternative dosing strategies for piperacillin/tazobactam: a systematic review and meta-analysis. <i>PLoS One</i>. 2015;10(1):e0116769. doi: 10.1371/journal.pone.0116769.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/piperacillin-and-tazobactam-sodium-drug-information/abstract-text/25575030/pubmed\" target=\"_blank\" id=\"25575030\">25575030</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zaki SA, Lad V. Piperacillin-Tazobactam-Induced Hypokalemia and Metabolic Alkalosis. <i>Indian J Pharmacol.</i> 2011;43(5):609-610.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/piperacillin-and-tazobactam-sodium-drug-information/abstract-text/22022014/pubmed\" target=\"_blank\" id=\"22022014\">22022014</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zobell JT, Waters CD, Young DC, et al. Optimization of Anti-Pseudomonal Antibiotics for Cystic Fibrosis Pulmonary Exacerbations: II. Cephalosporins and Penicillins. <i>Pediatr Pulmonol</i>. 2013;48(2):107-122.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/piperacillin-and-tazobactam-sodium-drug-information/abstract-text/22949297/pubmed\" target=\"_blank\" id=\"22949297\">22949297</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zosyn (piperacillin/tazobactam) [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals; May 2017.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9777 Version 166.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F210401\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F210402\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F210424\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F210405\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F210418\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F210406\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F210407\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F210408\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F210378\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F210362\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F210382\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F210381\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25470612\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F210432\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F210369\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F210385\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F210366\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299884\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F210371\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F210387\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F210388\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F210389\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F210376\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F210365\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F210384\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F6856652\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F210390\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9777|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=piperacillin-and-tazobactam-sodium-patient-drug-information\" class=\"drug drug_patient\">Piperacillin and tazobactam sodium: Patient drug information</a></li><li><a href=\"topic.htm?path=piperacillin-and-tazobactam-sodium-pediatric-drug-information\" class=\"drug drug_pediatric\">Piperacillin and tazobactam sodium: Pediatric drug information</a></li></ul></div></div>","javascript":null}